Table 1 Open in new tab Comparison of...

Variable	non-CR (n = 293)	pCR (n = 48)	P-value
Age (years) (n = 341)	63.0 (55.0–71.00)	63.0 (57.5–72.8)	0.626^*
Gender	Female	64 (22%)	14 (29%)	0.263#
Male	229 (78%)	34 (71%)
BMI (Kg/m²) (n = 341)	25.5 (23.1–28.1)	26.3 (23.8–28.7)	0.134^*
RCS Charlson-Index	0	0 (0%)	0 (0%)	0.398#
1	168 (57%)	25 (52%)
2	77 (26%)	17 (35%)
≥3	46 (17%)	6 (13%)
uT-Stage	T0/Tis	2 (1%)	1 (2%)	0.534#
T1	6 (2%)	1 (2%)
T2	34 (12%)	8 (17%)
T3	195 (66%)	29 (60%)
T4	30 (10%)	3 (6%)
NA	26 (9%)	6 (13%)
uN-Stage	uN-	61 (21%)	10 (21%)	0.949#
uN+	203 (69%)	33 (69%)
NA	29 (10%)	5 (10%)
cM-Stage	cM0	254 (87%)	43 (90%)	0.775#
cMX/1	39 (13%)	5 (10%)
Grading	GX	114 (38%)	20 (42%)	0.559#
G1	8 (3%)	3 (6%)
G2	87 (30%)	12 (25%)
G3	84 (29%)	13 (27%)
Neoadjuvant Chemotherapy	248 (85%)	38 (79%)	0.339#
Thereof: % FLOT	239 (96%)	37 (97%)
Neoadjuvant Chemoradiation	45 (15%)	10 (21%)
Thereof: % CROSS	38 (84%)	7 (70%)
Radiation Dosage (Gy) (n = 45)	41.4 (41.4–41.4)	41.4 (41.4–41.4)	0.969^*
Premature discontinuation of neoadjuvant treatment	16 (6%)	4 (8%)	0.628#
Days from end of neoadjuvant treatment to surgery (n = 288)	43 (35–57)	43 (36–55)	0.850^*
RECIST 1.1	CR/PR	128 (63%)	29 (81%)	0.045#
Procedure	2-Field-Esophagectomy	177 (60%)	37 (77%)	0.405#
3-Field-Esophagectomy	2 (1%)	0 (0%)
Transhiatal-extended gastrectomy	32 (11%)	2 (4%)
Gastrectomy	37 (13%)	7 (15%)
Subtotal Gastrectomy	30 (10%)	1 (2%)
Gastrectomy+HIPEC	13 (5%)	1 (2%)
Esophagogastrectomy	1 (0%)	0 (0%)
CCI (n = 341)	20.9 (0–40.6)	22.6 (0–39.7)	0.373^*
Length of Hospital Stay (days) (n = 341)	14.0 (11.0–18.0)	15.0 (13.0–21.0)	0.069^*
Pathological T-Stage	ypT0	8 (3%)	48 (100%)	<0.001#
ypT1	66 (22%)	0 (0%)
ypT2	57 (20%)	0 (0%)
ypT3	138 (47%)	0 (0%)
ypT4	24 (8%)	0 (0%)
Pathological N-Stage	ypN0	147 (50%)	48 (100%)	<0.001#
ypN1	61 (21%)	0 (0%)
ypN2	34 (12%)	0 (0%)
ypN3	51 (17%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	22 (46%)
(LN-/Reg-)	NA	26 (54%)
Postneoadjuvant M-Stage	yM0	256 (87%)	48 (100%)	0.009#
ypM1	37 (13%)	0 (0%)
R-Status	R0	278 (95%)	48 (100%)	0.109#
R1	15 (5%)	0 (0%)
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	48 (100%)	<0.001#
UICC-Stage I	59 (20%)	0 (0%)
UICC-Stage II	92 (31%)	0 (0%)
UICC-Stage III	71 (24%)	0 (0%)
UICC-Stage IV	71 (24%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	8 (3%)	48 (100%)	<0.001#
Grade 1b—Subtotal regression (<10% residual tumor)	92 (31%)	0 (0%)
Grade 2 – partial regression (10–50% residual tumor)	88 (30%)	0 (0%)
Grade 3 – no regression (>50% residual tumor)	95 (33%)	0 (0%)
Grade of regression not assessed	10 (3%)	0 (0%)
Adjuvant Treatment (% of patients receiving neoadjuvant CTx)	Yes	161 (73%)	28 (74%)	0.882#

Variable

non-CR (n = 293)

pCR (n = 48)

P-value

Age (years) (n = 341)

63.0 (55.0–71.00)

63.0 (57.5–72.8)

0.626^*

Gender

Female

64 (22%)

14 (29%)

0.263#

Male

229 (78%)

34 (71%)

BMI (Kg/m²) (n = 341)

25.5 (23.1–28.1)

26.3 (23.8–28.7)

0.134^*

RCS Charlson-Index

0 (0%)

0.398#

168 (57%)

25 (52%)

77 (26%)

17 (35%)

≥3

46 (17%)

6 (13%)

uT-Stage

T0/Tis

2 (1%)

1 (2%)

0.534#

6 (2%)

1 (2%)

34 (12%)

8 (17%)

195 (66%)

29 (60%)

30 (10%)

3 (6%)

26 (9%)

6 (13%)

uN-Stage

uN-

61 (21%)

10 (21%)

0.949#

uN+

203 (69%)

33 (69%)

29 (10%)

5 (10%)

cM-Stage

cM0

254 (87%)

43 (90%)

0.775#

cMX/1

39 (13%)

5 (10%)

Grading

114 (38%)

20 (42%)

0.559#

8 (3%)

3 (6%)

87 (30%)

12 (25%)

84 (29%)

13 (27%)

Neoadjuvant Chemotherapy

248 (85%)

38 (79%)

0.339#

Thereof: % FLOT

239 (96%)

37 (97%)

Neoadjuvant Chemoradiation

45 (15%)

10 (21%)

Thereof: % CROSS

38 (84%)

7 (70%)

Radiation Dosage (Gy) (n = 45)

41.4 (41.4–41.4)

0.969^*

Premature discontinuation of neoadjuvant treatment

16 (6%)

4 (8%)

0.628#

Days from end of neoadjuvant treatment to surgery (n = 288)

43 (35–57)

43 (36–55)

0.850^*

RECIST 1.1

CR/PR

128 (63%)

29 (81%)

0.045#

Procedure

2-Field-Esophagectomy

177 (60%)

37 (77%)

0.405#

3-Field-Esophagectomy

2 (1%)

0 (0%)

Transhiatal-extended gastrectomy

32 (11%)

2 (4%)

Gastrectomy

37 (13%)

7 (15%)

Subtotal Gastrectomy

30 (10%)

1 (2%)

Gastrectomy+HIPEC

13 (5%)

1 (2%)

Esophagogastrectomy

1 (0%)

0 (0%)

CCI (n = 341)

20.9 (0–40.6)

22.6 (0–39.7)

0.373^*

Length of Hospital Stay (days) (n = 341)

14.0 (11.0–18.0)

15.0 (13.0–21.0)

0.069^*

Pathological T-Stage

ypT0

8 (3%)

48 (100%)

<0.001#

ypT1

66 (22%)

0 (0%)

ypT2

57 (20%)

0 (0%)

ypT3

138 (47%)

0 (0%)

ypT4

24 (8%)

0 (0%)

Pathological N-Stage

ypN0

147 (50%)

48 (100%)

<0.001#

ypN1

61 (21%)

0 (0%)

ypN2

34 (12%)

0 (0%)

ypN3

51 (17%)

0 (0%)

Tumor regression in lymphnodes in pCR-patients

(LN-/Reg+)/Grade A

22 (46%)

(LN-/Reg-)

26 (54%)

Postneoadjuvant M-Stage

yM0

256 (87%)

48 (100%)

0.009#

ypM1

37 (13%)

0 (0%)

R-Status

278 (95%)

48 (100%)

0.109#

15 (5%)

0 (0%)

Postoperative UICC-Stage

UICC-Stage 0

0 (0%)

48 (100%)

<0.001#

UICC-Stage I

59 (20%)

0 (0%)

UICC-Stage II

92 (31%)

0 (0%)

UICC-Stage III

71 (24%)

0 (0%)

UICC-Stage IV

71 (24%)

0 (0%)

Histopathologic Regression

Grade 1a - No residual tumor

8 (3%)

48 (100%)

<0.001#

Grade 1b—Subtotal regression (<10% residual tumor)

92 (31%)

0 (0%)

Grade 2 – partial regression (10–50% residual tumor)

88 (30%)

0 (0%)

Grade 3 – no regression (>50% residual tumor)

95 (33%)

0 (0%)

Grade of regression not assessed

10 (3%)

0 (0%)

Adjuvant Treatment (% of patients receiving neoadjuvant CTx)

Yes

161 (73%)

28 (74%)

0.882#

Variable	non-CR (n = 293)	pCR (n = 48)	P-value
Age (years) (n = 341)	63.0 (55.0–71.00)	63.0 (57.5–72.8)	0.626^*
Gender	Female	64 (22%)	14 (29%)	0.263#
Male	229 (78%)	34 (71%)
BMI (Kg/m²) (n = 341)	25.5 (23.1–28.1)	26.3 (23.8–28.7)	0.134^*
RCS Charlson-Index	0	0 (0%)	0 (0%)	0.398#
1	168 (57%)	25 (52%)
2	77 (26%)	17 (35%)
≥3	46 (17%)	6 (13%)
uT-Stage	T0/Tis	2 (1%)	1 (2%)	0.534#
T1	6 (2%)	1 (2%)
T2	34 (12%)	8 (17%)
T3	195 (66%)	29 (60%)
T4	30 (10%)	3 (6%)
NA	26 (9%)	6 (13%)
uN-Stage	uN-	61 (21%)	10 (21%)	0.949#
uN+	203 (69%)	33 (69%)
NA	29 (10%)	5 (10%)
cM-Stage	cM0	254 (87%)	43 (90%)	0.775#
cMX/1	39 (13%)	5 (10%)
Grading	GX	114 (38%)	20 (42%)	0.559#
G1	8 (3%)	3 (6%)
G2	87 (30%)	12 (25%)
G3	84 (29%)	13 (27%)
Neoadjuvant Chemotherapy	248 (85%)	38 (79%)	0.339#
Thereof: % FLOT	239 (96%)	37 (97%)
Neoadjuvant Chemoradiation	45 (15%)	10 (21%)
Thereof: % CROSS	38 (84%)	7 (70%)
Radiation Dosage (Gy) (n = 45)	41.4 (41.4–41.4)	41.4 (41.4–41.4)	0.969^*
Premature discontinuation of neoadjuvant treatment	16 (6%)	4 (8%)	0.628#
Days from end of neoadjuvant treatment to surgery (n = 288)	43 (35–57)	43 (36–55)	0.850^*
RECIST 1.1	CR/PR	128 (63%)	29 (81%)	0.045#
Procedure	2-Field-Esophagectomy	177 (60%)	37 (77%)	0.405#
3-Field-Esophagectomy	2 (1%)	0 (0%)
Transhiatal-extended gastrectomy	32 (11%)	2 (4%)
Gastrectomy	37 (13%)	7 (15%)
Subtotal Gastrectomy	30 (10%)	1 (2%)
Gastrectomy+HIPEC	13 (5%)	1 (2%)
Esophagogastrectomy	1 (0%)	0 (0%)
CCI (n = 341)	20.9 (0–40.6)	22.6 (0–39.7)	0.373^*
Length of Hospital Stay (days) (n = 341)	14.0 (11.0–18.0)	15.0 (13.0–21.0)	0.069^*
Pathological T-Stage	ypT0	8 (3%)	48 (100%)	<0.001#
ypT1	66 (22%)	0 (0%)
ypT2	57 (20%)	0 (0%)
ypT3	138 (47%)	0 (0%)
ypT4	24 (8%)	0 (0%)
Pathological N-Stage	ypN0	147 (50%)	48 (100%)	<0.001#
ypN1	61 (21%)	0 (0%)
ypN2	34 (12%)	0 (0%)
ypN3	51 (17%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	22 (46%)
(LN-/Reg-)	NA	26 (54%)
Postneoadjuvant M-Stage	yM0	256 (87%)	48 (100%)	0.009#
ypM1	37 (13%)	0 (0%)
R-Status	R0	278 (95%)	48 (100%)	0.109#
R1	15 (5%)	0 (0%)
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	48 (100%)	<0.001#
UICC-Stage I	59 (20%)	0 (0%)
UICC-Stage II	92 (31%)	0 (0%)
UICC-Stage III	71 (24%)	0 (0%)
UICC-Stage IV	71 (24%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	8 (3%)	48 (100%)	<0.001#
Grade 1b—Subtotal regression (<10% residual tumor)	92 (31%)	0 (0%)
Grade 2 – partial regression (10–50% residual tumor)	88 (30%)	0 (0%)
Grade 3 – no regression (>50% residual tumor)	95 (33%)	0 (0%)
Grade of regression not assessed	10 (3%)	0 (0%)
Adjuvant Treatment (% of patients receiving neoadjuvant CTx)	Yes	161 (73%)	28 (74%)	0.882#

Variable

non-CR (n = 293)

pCR (n = 48)

P-value

Age (years) (n = 341)

63.0 (55.0–71.00)

63.0 (57.5–72.8)

0.626^*

Gender

Female

64 (22%)

14 (29%)

0.263#

Male

229 (78%)

34 (71%)

BMI (Kg/m²) (n = 341)

25.5 (23.1–28.1)

26.3 (23.8–28.7)

0.134^*

RCS Charlson-Index

0 (0%)

0.398#

168 (57%)

25 (52%)

77 (26%)

17 (35%)

≥3

46 (17%)

6 (13%)

uT-Stage

T0/Tis

2 (1%)

1 (2%)

0.534#

6 (2%)

1 (2%)

34 (12%)

8 (17%)

195 (66%)

29 (60%)

30 (10%)

3 (6%)

26 (9%)

6 (13%)

uN-Stage

uN-

61 (21%)

10 (21%)

0.949#

uN+

203 (69%)

33 (69%)

29 (10%)

5 (10%)

cM-Stage

cM0

254 (87%)

43 (90%)

0.775#

cMX/1

39 (13%)

5 (10%)

Grading

114 (38%)

20 (42%)

0.559#

8 (3%)

3 (6%)

87 (30%)

12 (25%)

84 (29%)

13 (27%)

Neoadjuvant Chemotherapy

248 (85%)

38 (79%)

0.339#

Thereof: % FLOT

239 (96%)

37 (97%)

Neoadjuvant Chemoradiation

45 (15%)

10 (21%)

Thereof: % CROSS

38 (84%)

7 (70%)

Radiation Dosage (Gy) (n = 45)

41.4 (41.4–41.4)

0.969^*

Premature discontinuation of neoadjuvant treatment

16 (6%)

4 (8%)

0.628#

Days from end of neoadjuvant treatment to surgery (n = 288)

43 (35–57)

43 (36–55)

0.850^*

RECIST 1.1

CR/PR

128 (63%)

29 (81%)

0.045#

Procedure

2-Field-Esophagectomy

177 (60%)

37 (77%)

0.405#

3-Field-Esophagectomy

2 (1%)

0 (0%)

Transhiatal-extended gastrectomy

32 (11%)

2 (4%)

Gastrectomy

37 (13%)

7 (15%)

Subtotal Gastrectomy

30 (10%)

1 (2%)

Gastrectomy+HIPEC

13 (5%)

1 (2%)

Esophagogastrectomy

1 (0%)

0 (0%)

CCI (n = 341)

20.9 (0–40.6)

22.6 (0–39.7)

0.373^*

Length of Hospital Stay (days) (n = 341)

14.0 (11.0–18.0)

15.0 (13.0–21.0)

0.069^*

Pathological T-Stage

ypT0

8 (3%)

48 (100%)

<0.001#

ypT1

66 (22%)

0 (0%)

ypT2

57 (20%)

0 (0%)

ypT3

138 (47%)

0 (0%)

ypT4

24 (8%)

0 (0%)

Pathological N-Stage

ypN0

147 (50%)

48 (100%)

<0.001#

ypN1

61 (21%)

0 (0%)

ypN2

34 (12%)

0 (0%)

ypN3

51 (17%)

0 (0%)

Tumor regression in lymphnodes in pCR-patients

(LN-/Reg+)/Grade A

22 (46%)

(LN-/Reg-)

26 (54%)

Postneoadjuvant M-Stage

yM0

256 (87%)

48 (100%)

0.009#

ypM1

37 (13%)

0 (0%)

R-Status

278 (95%)

48 (100%)

0.109#

15 (5%)

0 (0%)

Postoperative UICC-Stage

UICC-Stage 0

0 (0%)

48 (100%)

<0.001#

UICC-Stage I

59 (20%)

0 (0%)

UICC-Stage II

92 (31%)

0 (0%)

UICC-Stage III

71 (24%)

0 (0%)

UICC-Stage IV

71 (24%)

0 (0%)

Histopathologic Regression

Grade 1a - No residual tumor

8 (3%)

48 (100%)

<0.001#

Grade 1b—Subtotal regression (<10% residual tumor)

92 (31%)

0 (0%)

Grade 2 – partial regression (10–50% residual tumor)

88 (30%)

0 (0%)

Grade 3 – no regression (>50% residual tumor)

95 (33%)

0 (0%)

Grade of regression not assessed

10 (3%)

0 (0%)

Adjuvant Treatment (% of patients receiving neoadjuvant CTx)

Yes

161 (73%)

28 (74%)

0.882#

Table 1

Open in new tab

Comparison of EAC-patients with neoadjuvant treatment

Variable		non-CR (n = 293)	pCR (n = 48)	P-value
Age (years) (n = 341)		63.0 (55.0–71.00)	63.0 (57.5–72.8)	0.626^*
Gender	Female	64 (22%)	14 (29%)	0.263#
Gender	Male	229 (78%)	34 (71%)	0.263#
BMI (Kg/m²) (n = 341)		25.5 (23.1–28.1)	26.3 (23.8–28.7)	0.134^*
RCS Charlson-Index	0	0 (0%)	0 (0%)	0.398#
	1	168 (57%)	25 (52%)
	2	77 (26%)	17 (35%)
	≥3	46 (17%)	6 (13%)
uT-Stage	T0/Tis	2 (1%)	1 (2%)	0.534#
	T1	6 (2%)	1 (2%)
	T2	34 (12%)	8 (17%)
	T3	195 (66%)	29 (60%)
	T4	30 (10%)	3 (6%)
	NA	26 (9%)	6 (13%)
uN-Stage	uN-	61 (21%)	10 (21%)	0.949#
	uN+	203 (69%)	33 (69%)
	NA	29 (10%)	5 (10%)
cM-Stage	cM0	254 (87%)	43 (90%)	0.775#
cM-Stage	cMX/1	39 (13%)	5 (10%)	0.775#
Grading	GX	114 (38%)	20 (42%)	0.559#
	G1	8 (3%)	3 (6%)
	G2	87 (30%)	12 (25%)
	G3	84 (29%)	13 (27%)
Neoadjuvant Chemotherapy		248 (85%)	38 (79%)	0.339#
Thereof: % FLOT		239 (96%)	37 (97%)
Neoadjuvant Chemoradiation		45 (15%)	10 (21%)
Thereof: % CROSS		38 (84%)	7 (70%)
Radiation Dosage (Gy) (n = 45)		41.4 (41.4–41.4)	41.4 (41.4–41.4)	0.969^*
Premature discontinuation of neoadjuvant treatment		16 (6%)	4 (8%)	0.628#
Days from end of neoadjuvant treatment to surgery (n = 288)		43 (35–57)	43 (36–55)	0.850^*
RECIST 1.1	CR/PR	128 (63%)	29 (81%)	0.045#
Procedure	2-Field-Esophagectomy	177 (60%)	37 (77%)	0.405#
	3-Field-Esophagectomy	2 (1%)	0 (0%)
	Transhiatal-extended gastrectomy	32 (11%)	2 (4%)
	Gastrectomy	37 (13%)	7 (15%)
	Subtotal Gastrectomy	30 (10%)	1 (2%)
	Gastrectomy+HIPEC	13 (5%)	1 (2%)
	Esophagogastrectomy	1 (0%)	0 (0%)
CCI (n = 341)		20.9 (0–40.6)	22.6 (0–39.7)	0.373^*
Length of Hospital Stay (days) (n = 341)		14.0 (11.0–18.0)	15.0 (13.0–21.0)	0.069^*
Pathological T-Stage	ypT0	8 (3%)	48 (100%)	<0.001#
	ypT1	66 (22%)	0 (0%)
	ypT2	57 (20%)	0 (0%)
	ypT3	138 (47%)	0 (0%)
	ypT4	24 (8%)	0 (0%)
Pathological N-Stage	ypN0	147 (50%)	48 (100%)	<0.001#
	ypN1	61 (21%)	0 (0%)
	ypN2	34 (12%)	0 (0%)
	ypN3	51 (17%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	22 (46%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg-)	NA	26 (54%)
Postneoadjuvant M-Stage	yM0	256 (87%)	48 (100%)	0.009#
Postneoadjuvant M-Stage	ypM1	37 (13%)	0 (0%)	0.009#
R-Status	R0	278 (95%)	48 (100%)	0.109#
R-Status	R1	15 (5%)	0 (0%)	0.109#
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	48 (100%)	<0.001#
	UICC-Stage I	59 (20%)	0 (0%)
	UICC-Stage II	92 (31%)	0 (0%)
	UICC-Stage III	71 (24%)	0 (0%)
	UICC-Stage IV	71 (24%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	8 (3%)	48 (100%)	<0.001#
	Grade 1b—Subtotal regression (<10% residual tumor)	92 (31%)	0 (0%)
	Grade 2 – partial regression (10–50% residual tumor)	88 (30%)	0 (0%)
	Grade 3 – no regression (>50% residual tumor)	95 (33%)	0 (0%)
	Grade of regression not assessed	10 (3%)	0 (0%)
Adjuvant Treatment (% of patients receiving neoadjuvant CTx)	Yes	161 (73%)	28 (74%)	0.882#

Variable		non-CR (n = 293)	pCR (n = 48)	P-value
Age (years) (n = 341)		63.0 (55.0–71.00)	63.0 (57.5–72.8)	0.626^*
Gender	Female	64 (22%)	14 (29%)	0.263#
Gender	Male	229 (78%)	34 (71%)	0.263#
BMI (Kg/m²) (n = 341)		25.5 (23.1–28.1)	26.3 (23.8–28.7)	0.134^*
RCS Charlson-Index	0	0 (0%)	0 (0%)	0.398#
	1	168 (57%)	25 (52%)
	2	77 (26%)	17 (35%)
	≥3	46 (17%)	6 (13%)
uT-Stage	T0/Tis	2 (1%)	1 (2%)	0.534#
	T1	6 (2%)	1 (2%)
	T2	34 (12%)	8 (17%)
	T3	195 (66%)	29 (60%)
	T4	30 (10%)	3 (6%)
	NA	26 (9%)	6 (13%)
uN-Stage	uN-	61 (21%)	10 (21%)	0.949#
	uN+	203 (69%)	33 (69%)
	NA	29 (10%)	5 (10%)
cM-Stage	cM0	254 (87%)	43 (90%)	0.775#
cM-Stage	cMX/1	39 (13%)	5 (10%)	0.775#
Grading	GX	114 (38%)	20 (42%)	0.559#
	G1	8 (3%)	3 (6%)
	G2	87 (30%)	12 (25%)
	G3	84 (29%)	13 (27%)
Neoadjuvant Chemotherapy		248 (85%)	38 (79%)	0.339#
Thereof: % FLOT		239 (96%)	37 (97%)
Neoadjuvant Chemoradiation		45 (15%)	10 (21%)
Thereof: % CROSS		38 (84%)	7 (70%)
Radiation Dosage (Gy) (n = 45)		41.4 (41.4–41.4)	41.4 (41.4–41.4)	0.969^*
Premature discontinuation of neoadjuvant treatment		16 (6%)	4 (8%)	0.628#
Days from end of neoadjuvant treatment to surgery (n = 288)		43 (35–57)	43 (36–55)	0.850^*
RECIST 1.1	CR/PR	128 (63%)	29 (81%)	0.045#
Procedure	2-Field-Esophagectomy	177 (60%)	37 (77%)	0.405#
	3-Field-Esophagectomy	2 (1%)	0 (0%)
	Transhiatal-extended gastrectomy	32 (11%)	2 (4%)
	Gastrectomy	37 (13%)	7 (15%)
	Subtotal Gastrectomy	30 (10%)	1 (2%)
	Gastrectomy+HIPEC	13 (5%)	1 (2%)
	Esophagogastrectomy	1 (0%)	0 (0%)
CCI (n = 341)		20.9 (0–40.6)	22.6 (0–39.7)	0.373^*
Length of Hospital Stay (days) (n = 341)		14.0 (11.0–18.0)	15.0 (13.0–21.0)	0.069^*
Pathological T-Stage	ypT0	8 (3%)	48 (100%)	<0.001#
	ypT1	66 (22%)	0 (0%)
	ypT2	57 (20%)	0 (0%)
	ypT3	138 (47%)	0 (0%)
	ypT4	24 (8%)	0 (0%)
Pathological N-Stage	ypN0	147 (50%)	48 (100%)	<0.001#
	ypN1	61 (21%)	0 (0%)
	ypN2	34 (12%)	0 (0%)
	ypN3	51 (17%)	0 (0%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg+)/Grade A	NA	22 (46%)
Tumor regression in lymphnodes in pCR-patients	(LN-/Reg-)	NA	26 (54%)
Postneoadjuvant M-Stage	yM0	256 (87%)	48 (100%)	0.009#
Postneoadjuvant M-Stage	ypM1	37 (13%)	0 (0%)	0.009#
R-Status	R0	278 (95%)	48 (100%)	0.109#
R-Status	R1	15 (5%)	0 (0%)	0.109#
Postoperative UICC-Stage	UICC-Stage 0	0 (0%)	48 (100%)	<0.001#
	UICC-Stage I	59 (20%)	0 (0%)
	UICC-Stage II	92 (31%)	0 (0%)
	UICC-Stage III	71 (24%)	0 (0%)
	UICC-Stage IV	71 (24%)	0 (0%)
Histopathologic Regression	Grade 1a - No residual tumor	8 (3%)	48 (100%)	<0.001#
	Grade 1b—Subtotal regression (<10% residual tumor)	92 (31%)	0 (0%)
	Grade 2 – partial regression (10–50% residual tumor)	88 (30%)	0 (0%)
	Grade 3 – no regression (>50% residual tumor)	95 (33%)	0 (0%)
	Grade of regression not assessed	10 (3%)	0 (0%)
Adjuvant Treatment (% of patients receiving neoadjuvant CTx)	Yes	161 (73%)	28 (74%)	0.882#

^*Mann–Whitney-U-test

^#Pearson’s chi squared-test

This Feature Is Available To Subscribers Only